HRSA Posts Novartis Notice About 340B Refunds on a Top-Selling Drug—With Contract Pharmacy Strings Attached (Updated)
The U.S. Health Resources and Services Administration (HRSA) has posted drug manufacturer Novartis’ public notice to certain 340B hospitals that they might be eligible for refunds for overcharges on the company’s second-best selling drug—but only if the purchases comport with Novartis’ 340B contract pharmacy policy, which HRSA has said is illegal.
